Vaccination with a modified vaccinia virus Ankara (MVA) -vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects
Howles, S.; Guimarães-Walker, A.; Yang, H.; Hancock, G.; di Gleria, K.; Tarragona-Fiol, T.; Hayes, P.; Gilmour, J.; Bridgeman, A.; Hanke, T.áš; McMichael, A.; Dorrell, L.
Vaccine 28(45): 7306-7312
2010
ISSN/ISBN: 1873-2518
PMID: 20816902
DOI: 10.1016/j.vaccine.2010.08.077
Accession: 056829695
We investigated whether vaccination of healthy HIV-seronegative and HIV-1-seropositive antiretroviral therapy-treated subjects with recombinant modified vaccinia virus Ankara expressing an HIV-1 immunogen (MVA.HIVA) induced MVA-specific T cell responses. Using IFN-γ Elispot assays, we observed new or increased responses to MVA virus in 52% of HIV-seronegative subjects and 93% HIV-1 seropositive subjects; MVA-specific T cell frequencies were generally low and correlated poorly with T cell responses to the HIV-1 immunogen. In two vaccinees, responses were mapped to CD8+ T cell epitopes present in replication-competent vaccinia virus. These data support further evaluation of MVA as a viral vector for HIV-1 immunogens.